anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A quick-acting insulin preparation is prepared by dissolving insulin derived from pig pancreas in an aqueous injectable medium having or being given a pH value of between 7 and 8.  A solution of a compound of one or more metals that are prerequisite to the crystallization of insulin, i.e. zinc, cobalt, nickel or cadmium may be added providing the total metal content of the solution does not exceed about 13 X A X 10-13 milli equivalents per litre, A being the number of international units of insulin per millilitic.  Buffering agents, for example, phosphate, citrate, acetate, borate, maleate, diethyl barbiturate and glycerol buffers may also be present.  If the buffer used is capable of forming complexes with the metal ions present, the amount of metal compound added may exceed the above stated amount providing the free metal ions in solution do not exceed the limit. An example given is the preparation of an 0.02M aqueous solution of sodium acetate containing per litre 1.74 gms. (40,000 international units) of crystalline insulin derived from pig pancreas and containing about 0.7% zinc, 2 ml. N hydrochloric acid, 1 gm. methyl-p-hydroxybenzoate, 1.4% by weight NaCl, the pH being adjusted to 7.3 to 7.5 with sodium hydroxide.
Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory bone disease predominantly affecting the metaphyses of long bones and is usually seen in children. Although CRMO is generally a pediatric disease, it may also occur in adults. This may result in a delay in the diagnosis of adult-onset CRMO. This report presents an adult-onset female patient who presented with left leg pain followed by swelling in the right knee. The patient was initially started on colchicine treatment, but, due to unresponsiveness in the follow-up the patient, the treatment was switched to a combination of methotrexate and prednisolone. A satisfactory clinical recovery was achieved with these drugs. CRMO could be considered in the differential diagnosis of patients presenting with bone pain and joint complaints. Considering that the disease progresses with clinical flare-ups and remission periods, it should be kept in mind that patients should be followed closely and treatment can be changed.
The intestinal barrier consists of mucosal, epithelial, and immunological barriers and serves as a dynamic interface between the host and its environment. Disruption of the intestinal barrier integrity is a leading cause of various gastrointestinal diseases, such as inflammatory bowel disease. The homeostasis of the intestinal barrier is tightly regulated by crosstalk between gut microbes and the immune system; however, the implication of the immune system on the imbalance of gut microbes that disrupts barrier integrity remains to be fully elucidated. An inhibitory immunoglobulin-like receptor, Allergin-1, is expressed on mast cells and dendritic cells and inhibits Toll-like receptor (TLR)-2 and TLR-4 signaling in these cells. Since TLRs are major sensors of microbiota and are involved in local epithelial homeostasis, we investigated the role of Allergin-1 in maintaining intestinal homeostasis. Allergin-1-deficient (Milr1-/-) mice exhibited more severe dextran sulfate sodium (DSS)-induced colitis than did wild-type (WT) mice. Milr1-/- mice showed an enhanced intestinal permeability compared with WT mice even before DSS administration. Treatment of Milr1-/- mice with neomycin, but not ampicillin, restored intestinal barrier integrity. The 16S rRNA gene sequencing analysis demonstrated that Bifidobacterium pseudolongum was the dominant bacterium in Milr1-/- mice after treatment with ampicillin. Although the transfer of B. pseudolongum to germ-free WT mice had no effect on intestinal permeability, its transfer into ampicillin-treated WT mice enhanced intestinal permeability. These results demonstrated that Allergin-1 deficiency enhanced intestinal dysbiosis with expanded B. pseudolongum, which contributes to intestinal barrier dysfunction in collaboration with neomycin-sensitive and ampicillin-resistant microbiota.
Before the restorative treatment of mandibular first molar, inferior alveolar nerve block will be provided using the direct standard method. The 27 gauge needle of a 2ml disposable plastic syringe (Ayset, Adana, Turkey) enters from the intersection of the internal oblique edge and the midline of the pterygomandibular raphe, and 1 ml of 4% articaine solution containing1:100,000 epinephrine (Ultracaine DS Forte ampul, Sanofi-Aventis GmbH, Almanya) will be injected slowly in 60 seconds. 15 minutes after the injection the anaesthesia of the lip/tongue will be checked by probing the labial mucosa of the ipsilateral canine tooth.
The support (1) comprises a slip-resistant surface on its side turned to a mattress (2), where the support emits an active substance stimulating the fat metabolism in the body. A material emitting the active substance is embedded in the support. The active substance originates from sea alga or several types of alga, where the alga is Fucus Vesiculosus. The material emitting the active substance is embedded in an insert arranged between an upper- and a lower covering material layer. The alga or algae is/are embedded in the insert in dry form and in powder form. The support (1) comprises a slip-resistant surface on its side turned to a mattress (2), where the support emits an active substance stimulating the fat metabolism in the body. A material emitting the active substance is embedded in the support. The active substance originates from sea alga or several types of alga, where the alga is Fucus Vesiculosus. The material emitting the active substance is embedded in an insert arranged between an upper- and a lower covering material layer. The alga or algae is/are embedded in the insert in dry form and in powder form. The insert is formed by non-woven fabric and consists of pure new wool. The material emitting the active substance is fixed in the insert by steppe formation of the insert. The insert is interchangeable. The support is formed as a flat pad (9) with an area of less than 2x 1 m. A further pad is provided and emits the active substance. The active substance acts on a limbic system for controlling the appetite. The pad is provided as insert for a pillow (10).
BACKGROUND: Renal impairment has been previously linked to peripheral eosinophil count (PEC), prompting an investigation into its potential relationship with chronic kidney disease (CKD). This cross-sectional study utilized data from the National Health and Nutrition Examination Survey (NHANES 1999-2018) to comprehensively explore the association between PEC and CKD.
METHODS: Survey-weighted generalized multivariate linear regression was employed to evaluate the associations between PEC, urinary albumin-to-creatinine ratio (UACR), and estimated glomerular filtration rate (eGFR), with meticulous adjustment for potential covariates. To assess non-linear correlations, a restricted cubic spline analysis was conducted. Sensitivity analysis was performed to test the stability of results.
RESULTS: The study included a total of 9224 participants with non-dialysis CKD. In the multivariate linear regression model, after comprehensive adjustment for potential covariates, PEC showed a negative association with eGFR (β per 100 cells/uL increase in PEC, -0.71; 95% CI, -1.04, -0.37), while demonstrating a positive trend with UACR (β per 100 cells/uL increase in PEC, 10.21; 95% CI, 1.37, 19.06). The restrictive cubic spline curve analysis suggested that these associations occurred within the range of 0 to 400 cells/uL for PEC. Sensitivity analysis supported the stability of the observed results.
CONCLUSIONS: Circulating eosinophil levels are negatively correlated with eGFR and demonstrate a positive trend with UACR, when PEC falls within the range of less than 400 cells/uL among adults with CKD. Further research is warranted to validate these findings.
The overall study objective is to obtain data on the impact of the dietary incorporation of Chardonnay marc on measures of gut and cardiometabolic health. Towards this goal, an escalation design will be employed to examine the effects of 6 - 12 weeks of daily Chardonnay marc intake on markers of gut permeability, inflammation and cardiometabolic health in obese individuals. Study procedures will be performed during 3 study visits conducted at baseline, and after 6 and 12 weeks of Chardonnay Marc intake. For each study visit, 50 ml of blood (\~3.5 tbsp) will be collected. For the first six weeks of the study, the participants will be asked to incorporate 1.5 g of Chardonnay Marc into their diet between the hours of 11 am and 4 pm every day. This level of intake will be increased to 4.5 g of Chardonnay marc everyday from weeks 6-12. Therefore, all individuals will consume Chardonnay marc for at least 12 weeks. The participants will be instructed to not cook or add the Chardonnay Marc to hot foods, however, they will be allowed to add the Marc to tepid or warm foods and beverages. They will also be asked to log their intake and how they incorporated the Marc into their diet via a log.
CVD is the leading cause of death for women in the United States. It affects African American women at a higher rate than it does white women. People at risk for CVD are encouraged to maintain a healthy weight, eat a healthy diet that is low in fat and cholesterol, and increase their physical activity. Heath care centers are excellent places to provide counseling to people on ways to reduce their risk of CVD. In this study, researchers will evaluate the effectiveness of a community health care center-based counseling program aimed at reducing CVD risk factors among African American women from financially disadvantaged backgrounds.

This study will enroll African American women. Participants will be randomly assigned to one of two groups-either a basic program or a comprehensive program. During a routine, scheduled visit with their health care providers, all participants will learn about the importance of increasing physical activity and eating a low fat diet. All participants will also receive educational materials and a community resource guide. In addition to this, participants in the comprehensive program will receive a pedometer and will be asked to keep a daily log of their physical activity and eating habits. Once a month, these same participants will receive telephone calls from a health counselor and a newsletter by mail that encourages them to maintain a healthy lifestyle. All participants will receive home visits from study staff at baseline and Months 6 and 12. During these visits, participants will undergo blood pressure, weight, height, and waist measurements and a blood collection. Participants will complete questionnaires to assess their medical history, diet, and physical activity habits. For 1 week after each visit, participants will wear a physical activity monitor and keep an activity diary.
IMB model-based interventions were applied to the intervention group for 3 month. For the information component of the IMB model, diabetes education consisting of four sessions was given in groups of five in the first two weeks. Each patient was given a "Diabetes Management Education Booklet" prepared by the researchers. For the motivation component of the IMB model, total 5 sessions 30-minute motivational interview was made with individual Whatsapp calls once every two weeks starting from the third week.
The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. The F508del mutation results in protein misfolding, causing a defect in cellular processing and trafficking that targets the protein for degradation and therefore reduces the quantity of CFTR at the cell surface. The small amount of F508del-CFTR that reaches the cell surface is less stable and has low channel-open probability (defective gating activity) compared to wild-type CFTR protein.

Lumacaftor improves the conformational stability of F508del-CFTR, resulting in increased processing and trafficking of mature protein to the cell surface. Ivacaftor is a CFTR potentiator that facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein at the cell surface. In vitro studies have demonstrated that both lumacaftor and ivacaftor act directly on the CFTR protein in primary human bronchial epithelial cultures and other cell lines harboring the F508del-CFTR mutation to increase the quantity, stability, and function of F508del-CFTR at the cell surface, resulting in increased chloride ion transport. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.
PURPOSE: To provide a tramadol preparation for peroral administration suitable for the administration at intervals of at least 12 hr (e.g. max. 24 hr) for the treatment of pain. CONSTITUTION: This controlled release mixture for oral administration contains tramadol or its pharmacologically permissible salt as an active component. This mixture can slowly release the drug over a long period. Preferably, such mixture keeps the drug concentration in blood within a therapeutically effective range for >=12 hr.
Inhaled nitric oxide (NO) is used in the management of all causes of pediatric pulmonary hypertension. Despite widespread use of nitric oxide to treat critically ill mechanically-ventilated pediatric patients with pulmonary hypertension, response to therapy is not universal. Nitric oxide fails to improve oxygenation in approximately 30% of these patients. Nonresponders to nitric oxide have few treatment options. Iloprost is the only other medication approved for inhalational delivery in the treatment of pulmonary hypertension. Inhalation therapy for pulmonary vasodilatation in critically ill children is inherently more attractive than oral or intravenous therapies due to the ability to deliver medication directly to the lung and to decrease systemic effects. The use of inhaled iloprost has been reported to decrease pulmonary vascular resistance in many pediatric pathologic settings, including combination therapy with nitric oxide.
This is a randomized, controlled trial of a video- and telephone-based, brief insomnia treatment in Veterans who meet criteria for Insomnia Disorder and Posttraumatic Stress Disorder (PTSD) to accomplish the goal of improving psychosocial functioning. The primary outcome for the trial will be psychosocial functioning, with insomnia severity serving as the secondary outcome. Additional goals include assessing durability of treatment gains and evaluating whether suicidal ideation decreases after insomnia treatment. Eighty Veterans with Insomnia Disorder and PTSD will be randomly assigned to either Brief Behavioral Treatment for Insomnia (BBTI; one 60-minute and one 30-minute video encounter, and two 20-minute phone-based encounters) or a Progressive Muscle Relaxation Training control group (manualized relaxation training delivered by two video and two phone sessions, matched to the BBTI condition for therapist time). Prior to randomization, participants will complete clinician-administered, mental health diagnostic interviews at baseline (and post-treatment). Self-report measures of psychosocial functioning, insomnia severity, and other mental health symptoms will be completed at baseline (pretreatment), mid-treatment, post-treatment, and at 6-month follow-up (BBTI group only). Sleep parameters will be completed with a self-report sleep diary. One week of sleep parameters data will be collected at baseline and continuously to the post-treatment appointment (and at 6-month follow-up for the BBTI group only). The investigators also will explore whether BBTI decreases suicidal ideation, which often occurs in Veterans with PTSD and insomnia, using the Depressive Symptom Index: Suicidality Subscale and the Columbia Suicide Severity Rating Scale, the latter which is used clinically in VA to assess suicide risk.
This treatment includes participation in 4 one hour biweekly face-face sessions of cognitive behavioral therapy for insomnia, as well as a 15 minute telephone call on intervening weeks. The total intervention is 8 weeks.
PURPOSE:An antiallergic food consisting essentially of a coumarin. CONSTITUTION:An antiallergic food, consisting essentially of a coumarin, e.g. a compound expressed by formula I, II, III, IV or V, and capable of improving allergic symptoms, e.g. pollinosis, particularly by suppressing the formation of leukotriene which is a metabolite of arachidonic acid. The form of the food is a shape for eating 300-3,000mg coumarin by an intaking person a day, e.g. powder or refreshing drink, confectionary, staple food, bread, candy with a starch base, candy, etc. The compounds expressed by formulas I -V are obtained as follows; The compound expressed by formula I from flowers and tree barks of daphne; the compound expressed by formula II from tree barks of Japanese horse chestnut; the compound expressed by formula III from a plant of the family Umbelliferae, e.g. parsley; the compound expressed by formula IVfrom the root part of a plant of the family Umbelliferae, e.g. scopolia root; and the compound expressed by formula V from Periplocae radicis cortex.
White, circular, coated tablets. Flexible dosage: the starting dose will be 15 mg TID and the maximal dose 45 mg TID.
There are commercially available products that health insurance does not pay for to eliminate the odor caused by gas and stool output in patients with colostomy. The limited variety of these products in our country makes it difficult for patients to access the product. In addition, it was seen in the patient feedback that they thought these products had chemical content and were worried that they would damage the colostomy. For these reasons, there was a need to search for more accessible, affordable, and non-chemical products. Essential oils are volatile, aromatic, concentrated oily liquids taken from the essence of various plant parts. Research results on the antibacterial, antifungal, antiviral, antioxidative, and antimutagenic effects of plant essential oils are generally positive. Lavender essential oil and peppermint essential oil have been used in the past, for reasons such as creating a pleasant smell, providing wound healing, antibacterial and anxiolytic properties, and improving the quality of life. For this reason, it is accepted that the use of herbal essential oil and extract can be one effective solution. In the study of Kazemi et al. (2021); Lavender essential oil has also been found to be effective in wound healing. In Duluklu's (2018) study on patients with colostomy, it was determined that there was a significant improvement in the living conditions of the experimental group formed by dripping lavender oil into the colostomy bag. It was observed that there was a significant difference between the stoma compliance scale acceptance sub-dimension and the overall stoma compliance mean score. In rainbow trout, Metin et al. (2015), in his study; They found that the use of peppermint oil did not cause any toxic effects on fish. Anderson et al.) in a randomized double-blind study with individuals experiencing postoperative nausea and vomiting, given lisinopril alcohol, peppermint oil, and placebo (saline) effective products, and nausea determined at the second and fifth minutes following inhalation of peppermint oil applied to gauze before the application of peppermint oil extract. It was determined that it decreased significantly according to the feeling of nausea. In literature reviews; There are limited studies on using lavender essential oil for odor removal in individuals with colostomy. There is no use of peppermint essential oil. Using lavender oil and peppermint oil in a stoma bag is a simple, natural, and low-cost method for odor removal.
OBJECTIVE: Cardiac dysfunction can result from excessive fibrosis in cardiac fibroblasts (CFs) following an acute myocardial infarction (AMI). SIRT3 has been shown to be associated with numerous cardiovascular diseases. This study aimed to investigate the mechanism by which SIRT3 influences myocardial fibrosis following AMI.
METHODS: An AMI model was established in rats and echocardiography was used to assess cardiac systolic function. Triphenyl tetrazolium chloride (TTC) and H&E staining were employed to observe the myocardial histopathological status. Masson trichrome staining was used to detect fibrosis, and the changes in expression of fibrosis-related proteins were detected by Western Blot (WB). In this study, we utilized in vitro cell models stimulated by Ang II to investigate the underlying mechanisms. We employed Transwell and CCK-8 assays to detect the function of CFs. Additionally, we used transmission electron microscopy (TEM) to observe the structural morphology of mitochondria, whereas WB was performed to quantify fibrosis-associated proteins and to assay the changes in SIRT3, SRV2, and Drp1.
RESULTS: We observed a significant decrease in the expression of SIRT3 and an increase in mitochondrial fragmentation in rats with AMI. Additionally, we observed upregulation of fibrosis-associated signature proteins and collagen proteins expression. Through the use of vitro Ang II stimulation we observed a downregulation of SIRT3 expression, an increase in mitochondrial fragmentation, and an increase in the proliferation and migration of CFs. Opposite effects were observed when SIRT3 was overexpressed. Additive mitochondrial division agonists were found to stimulate the proliferation and migration of CFs, however, SIRT3 expression was unchanged. Interference with SRV2 and SIRT3 revealed that SIRT3 effectively prevented the expression of SRV2/Drp1, resulting in the inhibition of mitochondrial division and the suppression of CFs proliferative migration.
CONCLUSION: In summary, SIRT3 can suppress myocardial fibrosis after acute myocardial infarction by regulating SRV2/Drp1-mediated mitochondrial division.
Drug delivery compositions which are suitable for transvaginal administration for the treatment of diseases and disorders of the urogenital tract are described. The drug delivery compositions are administered directly to the vagina using a convenient transvaginal application that deposits a very small volume of drug at the desired site for delivery. This method of administration reduces the systemic levels of the drugs and decreases the side effects which are associated with systemic administration. In the preferred embodiment, the compositions are in the form of a gel. The formulation is administered in volumes of less than or equal to 1 milliliter. In the preferred embodiment, the composition contains an antimuscarinc drug, such as oxybutynin.
After the first interview with the patients in the intervention group, a phone call will be made for regarding the implementation of nursing interventions based on the Comfort Theory, and they will be informed about the planned dates for the implementation. The implementation phase of nursing interventions based on Comfort Theory will be carried out for 6 weeks at the Communication Laboratory of the Faculty of Nursing of Akdeniz University on the planned dates with the patients. In addition, a handbook will be given to the patients at the beginning of the practice, and the Home Yoga Diary in the handbook will be expected to be filled in daily by the patients during the research. Immediately after the implementation of the nursing interventions based on Comfort Theory (week 6), patients will be asked to fill in ISI, IQO-L, and the Urinary Incontinence and Frequency Comfort Scale. During this whole process, patients will continue their planned routine care and treatment.
Keep out of reach of children. For external use only. Avoid contact with the eyes. Some users may experience a mild skin irritation. If skin irritation becomes severe, stop use and consult a physician. Do not use on children under 12 years of age unless directed by a physician. If swallowed, get medical help or contact a Poison Control Center right away.